drugset / Trial / NCT01044329
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion
Phase 2
Unknown
90 enrolled
Shahid Beheshti University of Medical Sciences
Labbafinejad Medical Center · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
Timeline
- Start
- 2010-01
- Primary completion
- 2010-08
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Triamcinolone Acetonide | Other / unclassified | 2 mg | Intravitreal |